NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
Betsy Goodfellow | February 1, 2024 | News story | Medical Communications | AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment option for adults with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned or not responded to two previous treatments.
This recommendation follows data from the single-arm phase 1/2 EPCORE NHL-1 trial, which displayed a 62% overall response rate, meaning 62% of patients’ blood cancer was either reduced by half (partial response) or showed no evidence of disease from tests and scans (complete response). Complete response rate was 39%.
Rincy George, policy officer at Blood Cancer UK, commented: “Diffuse large B-cell lymphoma is a type of blood cancer and, while most people go into remission after standard treatment, some people can see their cancer return. Like many that experience blood cancer, people with relapsed or refractory DLBCL experience anxiety around the prospect of not responding to treatment or the cancer once again returning. Epcoritamab (Tepkinly), is an injectable bispecific antibody designed to recognise and attach to the cancer cells and immune cells, so that the body’s immune system can destroy them. Today’s decision from NICE approving epcoritamab for eligible patients for use on the NHS in England and Wales is a welcome step for many.”
Belinda Byrne, medical director at AbbVie UK, added: “AbbVie is committed to advancing care for people living with blood cancer. We are delighted that NICE has recognised the benefit that epcoritamab can have on the lives of people living with R/R DLBCL. We will continue working closely with the relevant authorities to provide equitable access across the UK for eligible R/R DLBCL patients in need.”
Betsy Goodfellow
Related Content
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
